News | October 27, 2022
Gland Pharma’s Q2 FY23 revenue stood at Rs. 1,044.4 Cr
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
Revenue from operations up 26% to Rs. 768 crores
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
This acquisition will accelerate Medcare's plans to emerge as an international hub for health, beauty, and wellness adding to its existing network of 4 hospitals and over 20 medical centres in the UAE.
The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.
The booster vaccination trial is still ongoing and further data will provide more information around safety and efficacy.
Transformation to pure-play Innovative Medicines company nears completion
The companies will leverage their respective proprietary technology platforms
Subscribe To Our Newsletter & Stay Updated
